<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01211002</url>
  </required_header>
  <id_info>
    <org_study_id>sim201002</org_study_id>
    <nct_id>NCT01211002</nct_id>
  </id_info>
  <brief_title>Study of Concurrent Chemo-radiotherapy Combined With Recombinant Human Endostatin for Local Advanced Non-small Cell Lung Cancer (NSCLC)</brief_title>
  <official_title>The Exploratory Clinical Study of Concurrent Chemo-radiotherapy Combined With Recombinant Human Endostatin (Endostar) for Local Advanced Non-small Cell Lung Cancer (NSCLC (Ⅲ A / Ⅲ B) )</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Simcere Pharmaceutical Co., Ltd</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Daping Hospital and the Research Institute of Surgery of the Third Military Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Simcere Pharmaceutical Co., Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is a trials to evaluate the overall survival (OS) of radiotherapy / EP combined with
      recombinant human endostatin in treatment of locally advanced (Ⅲ A / unresectable Ⅲ B)
      non-small cell lung cancer.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>October 2010</start_date>
  <completion_date type="Anticipated">December 2012</completion_date>
  <primary_completion_date type="Anticipated">December 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall survival (OS)</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>quality of life</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>objective response rate (ORR)</measure>
    <time_frame>1 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>disease control rate (DCR)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>progression-free survival (PFS)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">170</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>radiotherapy combined with EP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>the dose of radiotherapy is 60-66 Gy / 30-33f.The combination regimen is etoposide (50 mg/m2 day1-5, 29-33) and cisplatin (50 mg/m2 day1, 8, 29, 36) in the 1st, 4th weeks of radiotherapy for 2 courses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>adiotherapy / EP /recombinant human endostatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>recombinant human endostatin: The number of courses is 3 ~ 4 and each course last for 28 days.dose:15mg，d1-14, intravenous injection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiotherapy combined with EP</intervention_name>
    <description>Tumor vo lume is 60-66 Gy / 30-33f and the combination regimen is etoposide (50 mg/m2 day1-5, 29-33) and cisplatin (50 mg/m2 day1, 8, 29, 36) in the 1st, 4th weeks of radiotherapy for 2 courses.</description>
    <arm_group_label>radiotherapy combined with EP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>radiotherapy / EP combined with recombinant human endostatin</intervention_name>
    <description>Anti-vascular targeting therapy The number of courses is 3 ~ 4 and each course last for 28 days. Recombinant human endostatin（Endostar）：15mg，d1-14, intravenous injection.</description>
    <arm_group_label>adiotherapy / EP /recombinant human endostatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with pathologically or histologically confirmed and inoperable stage Ⅲ (Ⅲ A
             or unresectable Ⅲ B) NSCLC;

          2. Patients with ages of 18~70 years, general condition ECOG performance scale （PS）≤ 1,
             weight loss &lt;10% during last 6 months;

          3. CT films of patients during last 4 weeks were accessible when patients were selected
             into the groups, the lesions were measurable; (According to the standard of RECIST1.1,
             they should have at least one of accurately measurable lesions with the largest
             diameter ≥ 10mm by spiral CT, PET-CT, with the largest diameter≥ 20mm by ordinary CT
             and MRI.）

          4. No major organ dysfunction, the function of heart, liver and kidney was normal,
             laboratory indicators should meet the following requirements: Blood: WBC&gt; 4.0 × 109 /
             L, absolute neutrophil count &gt; 1.5 × 109 / L, platelet count&gt; 100 × 109 / L,
             hemoglobin&gt; 110g / L; liver function: serum bilirubin was less than 1.5 × maximum
             normal value ; ALT and AST were less than 1.5 × maximum normal value; BUN, Cr within
             the normal range; FEV1 &gt; 1L or&gt; 40% of predicted value;

          5. Patients could understand the circumstances of this study and those who have signed
             the informed consent form;

        Exclusion Criteria:

          1. Pregnant or lactating women; women of child-bearing age without contraception;

          2. Acute infection or other serious underlying diseases;

          3. Significant neurological, psychiatric history, including dementia which may influence
             the ability to understand and the informed consent;

          4. Receive the treatment of other experimental trials in the same period; on the
             medication of other anticancer drugs a the same time; have joined other drug clinical
             trials 30 days before this clinical trial;

          5. Diabetes without control (blood-glucose is unstable or ≥ 8mol / L after
             administration);

          6. Patients who are allergic to E. coli preparation;

          7. Patients who are unsuitable to participate in this trial determined by the
             researchers.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>zhenzhou yang, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Daping Hospital and the Research Institute of Surgery of the Third Military Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhenzhou Yang, M.D.</last_name>
    <email>yangzhenzhou@sohu.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Daping Hospital</name>
      <address>
        <city>Chongqin</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>zhenzhou yang, M.D.</last_name>
      <email>yangzhenzhou@sohu.com</email>
    </contact>
    <investigator>
      <last_name>zhenzhou yang, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 27, 2010</study_first_submitted>
  <study_first_submitted_qc>September 28, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 29, 2010</study_first_posted>
  <last_update_submitted>September 28, 2010</last_update_submitted>
  <last_update_submitted_qc>September 28, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 29, 2010</last_update_posted>
  <responsible_party>
    <name_title>Zhenzhou Yang M.D.</name_title>
    <organization>Daping Hospital and Research Institute of Surgery of Third Military Medical University</organization>
  </responsible_party>
  <keyword>Radiotherapy</keyword>
  <keyword>rh-endostatin</keyword>
  <keyword>chemotherapy</keyword>
  <keyword>NSCLC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endostatins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

